Nycomed seeks bidders for potential $13B sale

Swiss drugmaker Nycomed has hired Goldman Sachs to scout for buyers up for a $13.5 billion deal. Options include licensing Nycomed's experimental lung-disease drug, an IPO, or an outright sale of the entire company. The drugmaker's large business in Eastern Europe and Russia could make it attractive to Big Pharmas looking to grow in emerging markets. Report | Report